Amy Pace

Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

Sean J. Pittock, Achim Berthele, Kazuo Fujihara et al. · New England Journal of Medicine · 2019 · 846 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

Eva Havrdová, Steven Galetta, Michael Hutchinson et al. · The Lancet Neurology · 2009 · 473 citations

Life Sciences, Neurology, Pharmacotherapy +10

Comparison of the Timed 25-Foot and the 100-Meter Walk as Performance Measures in Multiple Sclerosis

Rémy Phan-Ba, Amy Pace, Philippe Calay et al. · Neurorehabilitation and neural repair · 2011 · 106 citations

Medicine, Neurology, Rehabilitation Medicine +17

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis

J. Theodore Phillips, Gavin Giovannoni, Fred Lublin et al. · Multiple Sclerosis Journal · 2011 · 102 citations

Medicine, Neurology, Disability Management +15

Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate

J. Theodore Phillips, Krzysztof Selmaj, Ralf Gold et al. · International Journal of MS Care · 2015 · 60 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +13